The combined therapies vemurafenib‐XL888 (Paraiso et al, 2012; NCT01657591) and the recent triple combination BRAFi‐MEKi‐XL888 (NCT02721459) are currently being tested in clinical trials in patients with melanoma harboring BRAF mutations. Here, BRAF is linked to melanoma.